Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891284 | 0.94 | PLA2G2A (0.54) | PLAUESR1THRATHRBPLA2G2A | |
| SCHEMBL1708361 | 0.88 | PLAU (0.68) | PLAUESR1THRATHRBPLA2G2A | |
| SCHEMBL1707251 | 0.85 | ESR1 (0.51) | PLAUESR1THRATHRBPLA2G2A | |
| SCHEMBL6557422 | 0.82 | PLA2G2A (0.64) | PLAUTHRATHRBPLA2G2ATP53 | |
| SCHEMBL12432454 | 0.82 | PLA2G2A (0.64) | PLAUTHRATHRBPLA2G2ATP53 | |
| SCHEMBL4898942 | 0.81 | THRA (0.55) | ESR1THRATHRBPLA2G2AKDM4E | |
| SCHEMBL566358 | 0.79 | PLAU (0.70) | PLAUPLA2G2ALMNAHTT | |
| SCHEMBL11346598 | 0.79 | S1PR2 (0.49) | PLAUESR1THRATHRBPLA2G2A | |
| SCHEMBL6559420 | 0.79 | S1PR2 (0.49) | PLAUESR1THRATHRBPLA2G2A | |
| SCHEMBL4890126 | 0.78 | GLRA1 (0.46) | THRATHRBPLA2G2ATP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| EP-1729756-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094810-A2 | NOVEL PHARMACEUTICAL COMPOSITIONS | KARO BIO AB (SE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | PLAU 1826/4885ESR1 58/4885THRA 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.